Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
LPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $4.79
Previous CloseN/A
Volume72.74K
Average Volume (3M)377.96K
Market Cap
$15.37M
Enterprise Value$43.46M
Total Cash (Recent Filing)$16.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.26
Next Earnings
May 19, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding38,317,898
10 Day Avg. Volume266,212
30 Day Avg. Volume377,956
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-101.78
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$3.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical DataEncouraging data in a niche CRC population showed a higher objective response rate for sirexatamab compared to the control group.
Regulatory PathwayManagement believes the data in CRC is strong enough to initiate a conversation with FDA to seek a regulatory pathway based on the positive objective response data in DeFianCe.
Bears Say
Clinical UpdatesWith limited insight into ongoing activities and no major clinical data updates for at least six months, the recommendation is moving to the sidelines awaiting clarity.
Financial PositionThe company's current cash position is insufficient to fund a Phase 3 clinical program, indicating a potential need for partnership.
Market PotentialSirexatamab did not show benefit in GEJ/G cancer, lowering the overall market potential of the drug.
---
Ownership Overview
6.24% Insiders
3.88% Mutual Funds
38.53% Other Institutional Investors
45.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics Inc’s price range in the past 12 months?
Leap Therapeutics Inc lowest stock price was $0.39 and its highest was $4.79 in the past 12 months.
What is Leap Therapeutics Inc’s market cap?
Leap Therapeutics Inc’s market cap is $15.37M.
When is Leap Therapeutics Inc’s upcoming earnings report date?
Leap Therapeutics Inc’s upcoming earnings report date is May 19, 2025 which is in 54 days.
How were Leap Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Leap Therapeutics Inc overvalued?
According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued.
Does Leap Therapeutics Inc pay dividends?
Leap Therapeutics Inc does not currently pay dividends.
What is Leap Therapeutics Inc’s EPS estimate?
Leap Therapeutics Inc’s EPS estimate is -0.41.
How many shares outstanding does Leap Therapeutics Inc have?
Leap Therapeutics Inc has 38,317,898 shares outstanding.
What happened to Leap Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Leap Therapeutics Inc?
Currently, no hedge funds are holding shares in LPTX
---
Leap Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (669.23% Upside)
$3.00 (669.23% Upside)
Blogger Sentiment
Bullish
LPTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $18.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.52%
12-Months-Change
Fundamentals
Return on Equity
-106.79%
Trailing 12-Months
Asset Growth
-21.67%
Trailing 12-Months
Company Description
Leap Therapeutics Inc
Leap Therapeutics, Inc. (LPTX) is a clinical-stage biopharmaceutical company dedicated to developing innovative monoclonal antibody therapies for the treatment of cancer. The company operates in the biotechnology and pharmaceutical sectors, focusing on the identification and advancement of novel therapeutic agents. Its core products include a pipeline of proprietary monoclonal antibodies targeting specific cancer pathways to enhance the body's immune response against tumors.
---
LPTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(669.23% Upside)
Technical Analysis
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-39.67%
assigned a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.67% per trade.
---